Analysis of Expression of the GRIPAP1, DLG4, KIF1B, NGFRAP1, and NRF1 Genes in Peripheral Blood of the Patients with Parkinson’s Disease in the Early Clinical Stages

---

Maria V. Lukashevich^1,a*, Margarita M. Rudenok¹, Ekaterina I. Semenova¹, Suzanna A. Partevian¹, Alexey V. Karabanov², Elena Yu. Fedotova², Sergey N. Illarioshkin², Petr A. Slominsky¹, Maria I. Shadrina¹, Anelya Kh. Alieva¹

¹National Research Centre “Kurchatov Institute”, 123182 Moscow, Russia

²Research Center of Neurology, 125367 Moscow, Russia

^* To whom correspondence should be addressed.

Received: May 14, 2024; Revised: September 19, 2024; Accepted: September 23, 2024

---

Parkinson’s disease (PD) is one of the most common progressive neurodegenerative diseases. An important feature of the disease is its long latent period, which necessitates search for prognostic biomarkers. One method of identifying biomarkers of PD is to study changes in gene expression in peripheral blood of the patients in early stages of the disease and have not been treated. In this study, we analyzed relative mRNA levels of the genes GRIPAP1, DLG4, KIF1B, NGFRAP1, and NRF1, which are associated with neurotransmitter transport, apoptosis, and mitochondrial dysfunction, in the peripheral blood of PD patients using reverse transcription and real-time PCR with TaqMan probes. The results of this study suggest that the GRIPAP1 and DLG4 genes could be considered as potential biomarkers for the early clinical stages of Parkinson’s disease. The data obtained may indicate that NGFRAP1 is involved in pathogenesis of both PD and other neurodegenerative diseases. Furthermore, in the early clinical stages of the disease we studied, the KIF1B and NRF1 genes were found not to be involved in PD pathogenesis at the expression level.

---

KEY WORDS: Parkinson’s disease, gene expression, peripheral blood

DOI: 10.1134/S0006297924100092

Publisher’s Note. Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---